A new mechanism of action to attack in the treatment of coronary artery disease (CAD), Novartis developed Ilaris (canakinumab), a human monoclonal antibody targeting the interleukin-1beta innate immunity pathway Reporter: Aviva Lev-Ari, PhD, RN Speaking at an ESC press briefing, Ridker said, “This is what personalized predictive medicine is all about.” Once a patient has […]